Clinical Trial Update: P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the P-Gemox chemotherapy regimen as first-line treatment for extranodal NK/T-cell lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Nk T-cell Lymphoma

Drugs mentioned

• P-GEMOX regimen

Snippet

Sponsor: Sun Yat-sen University | Conditions: Lymphoma, Extranodal NK-T-Cell | Phase 2 | Status: TERMINATED